

Test Report EN 1276 *VIBRIO CHOLERAE* Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of bactericidal activity of chemical disinfectants and antiseptics used in food, industrial, domestic and institutional areas (phase 2, step 1)

Test Laboratory

BluTest Laboratories Ltd

Robertson Incubator (4th Floor)
Robertson Building
University of Glasgow
57 Dumbarton Road
Glasgow
G11 6NU

Identification of sample

Name of the product
Project Code
Manufacturer
Date of Delivery
Storage Conditions
Active substances

DUOMAX DR1

BT-DUO-10
DUOTECH LTD, 11-12 QUEENS SQUARE, BRISTOL, BS1 4NT
29 October 2010
Room temperature
Unknown

Test Method and its validation

Method
Neutralizer

Filtration-neutralization
Lecithin 3g/l, Polysorbate 80 30g/l, sodium thiosulphate 5g/l, L-histidine 1g/l, phosphate buffer 0.0025mol/l, sterilized by autoclave

Experimental Conditions

Period of analysis
Product diluent used
Product test concentrations
Appearance product dilutions
Contact time
Test temperature
Interfering substance
Stability of mixture
Temperature of incubation
Identification of strains

13 to 14 January 2011
Sterile, synthetic hard water
10.0 % V/V; 20.0 % V/V; 80.0% V/V
Clear
 $t = 1 \text{ min} \pm 10 \text{ s}$; $t = 5 \text{ min} \pm 10 \text{ s}$
 $20^{\circ}\text{C} \pm 1^{\circ}\text{C}$
3.0 g/l bovine serum albumin
No precipitation
 $37^{\circ}\text{C} \pm 1^{\circ}\text{C}$
Vibrio cholerae (NCTC 8457)

Conclusion

According to testing carried out under conditions specified in EN 1276, **DUOMAX DR 1** possesses bactericidal activity at a concentration of 10.0 % V/V of the working concentration as tested after 5 minutes at 20°C under **DIRTY** conditions (3.0 g/l bovine serum albumin) for referenced strain *Vibrio cholerae* (NCTC 8457).

Signed



Dr Chris Woodall, Director
BluTest Laboratories Ltd
Glasgow, UK, 26 January 2011

EN 1276: *Vibrio cholerae* under DIRTY conditions for DUOMAX, DUOTECH LTD

Test organisms	Validation test				Bacterial test Suspension	Contact time	Test procedure at concentration (V/V) of the working concentration				%
	Bacterial Suspension	Experimental conditions	Neutralizer toxicity control or filtration control	Dilution- neutralization control or filtration test control				10	20	80	
<i>Vibrio cholerae</i> NCTC 8457	Vc:102; 132	Vc:67; 78	Vc:82; 89	Vc:85; 78	10 ⁻⁶ : >330;>330 10 ⁻⁷ :35; 39 N:3.70 x 10 ⁸	5 minutes	Vc	0; 0	0; 0	0; 0	
	Nv:1.17 x 10 ³	A: 7.25 x 10 ¹	B: 8.55 x 10 ¹	C: 8.15 x 10 ¹			Na R	<1.5 x 10 ² >10 ⁵	<1.5 x 10 ² >10 ⁵	<1.5 x 10 ² >10 ⁵	
		Vc:90; 102 A: 9.60 x 10 ²				1 minute	Vc Na R	0; 0 <1.5 x 10 ² >10 ⁵	0; 0 <1.5 x 10 ² >10 ⁵	0; 0 <1.5 x 10 ² >10 ⁵	
Vc = viable count N = number of cfu/ml of the bacterial test suspension Nv = number of cfu/ml in the bacterial suspension R = reduction in viability Na = number of cfu/ml in the test mixture A = number of cfu/ml of the experimental conditions validation B = number of cfu/ml of the neutralizer toxicity validation or of the filtration validation C = the number of cfu/ml of the dilution-neutralization validation or the membrane filtration test validation											

DISCLAIMER

BluTest (BT) has performed the Testing detailed in this report using reasonable skill and care and that BT has used reasonable endeavours to carry out the Testing [in accordance with a modified EN 1276 protocol]. All forecasts, recommendations and results contained in any report to the Company shall be submitted in good faith. However, other than as expressly set out in this report, no warranty is given (i) in relation to the Testing or the use(s) to which any results or deliverables produced in the course of the Testing are or may be put by the Company or their fitness or suitability for any particular purpose or under any special conditions notwithstanding that any such purpose or conditions may have been made known to BT or (ii) that the intended results or deliverables from the Testing can be achieved or (iii) that the Company can freely make use of the results or the deliverables without infringing any third party intellectual property rights and the Company will be deemed to have satisfied itself in this regard. BT shall have no liability (which is hereby excluded to the fullest extent permissible by law) in respect of any loss, liability or damage, including without limitation any indirect and/or consequential loss such as loss of profit or loss of business, market or goodwill, that the Company may suffer directly or indirectly as a result of or in connection with: (i) the performance of the Testing, except for direct loss arising from a breach of the foregoing warranties; (ii) the use of any materials, samples or other information provided by the Company for use in the Testing; and (iii) the Company's reliance upon or use of any results or deliverables provided as part of the Testing. The total liability of BT shall not exceed the sums paid to BT for the performance of the Testing.